Why Did Novavax Inc. (NVAX) Stock Rise 13.63% Today?

Novavax’s price jump was sparked by a fresh media spotlight: a Yahoo! Finance Canada article titled “Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It” went live within the last 48 hours, drawing attention to the vaccine maker’s recent product approvals and upcoming data releases. The story highlighted a pending submission to the FDA for a next‑generation COVID‑19 booster and a partnership with a major European distributor, both of which can be interpreted as catalysts for future revenue growth. The buzz translated into heavy buying, with 7.85 million shares changing hands—about 1.6 times the 30‑day average volume of 4.86 million—signaling that the move is driven by active trader interest rather than a routine price drift.

The broader market was flat, as the S&P 500 and Russell 2000 each posted essentially zero change. That flat backdrop means Novavax’s 13.6 % gain is clearly company‑specific; the sector that houses biotech and vaccine developers showed no notable movement, reinforcing the idea that the spike is tied to the news piece rather than a sector rally.

From a technical standpoint, the stock closed at $10.46, just shy of its 52‑week high of $11.97 and well above its 52‑week low of $6.13. The price now sits near the upper half of its range, suggesting momentum could carry it toward the next resistance level around $11.00‑$11.20.

Investors should keep an eye on any official FDA filings or partnership announcements that may follow the media coverage, as those events could shape the stock’s path in the next sessions.